Scholar Rock Holding Corporation (SRRK) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates solid financial performance, strategic global expansion, and strong cash runway into 2027. The Q&A session reveals proactive risk management and strategic financing, with a focus on minimizing operational disruptions and ensuring FDA compliance. Although some uncertainties exist regarding the reinspection timeline, the company's strategic investments and optimistic guidance suggest a positive outlook. The stock price is likely to increase by 2% to 8% over the next two weeks, driven by the company's strategic initiatives and financial health.
Key Financial Performance
Cash and Cash Equivalents $369.6 million at the end of the third quarter, reflecting a strong financial position.
Operating Expenses $103 million for the quarter, including $18.3 million in noncash stock-based compensation. Excluding stock-based compensation, operating expenses were $85.3 million, reflecting ongoing investments in infrastructure for regulatory approval, commercial readiness, and clinical pipeline.
Funds Raised $141.7 million added to the balance sheet during the third quarter. This includes $91.7 million from the sale of approximately 2.8 million shares through ATM and $50 million drawn from an existing debt facility.
Cash Runway Expected to fund operations into 2027, supported by approximately $60 million in cash from the exercise of outstanding common warrants by year-end.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Apitegromab: Apitegromab is being developed as a treatment for SMA (Spinal Muscular Atrophy). The Phase III SAPPHIRE study demonstrated its efficacy in improving motor function. However, its approval was delayed due to compliance issues at a third-party manufacturing facility. Scholar Rock is working to address this and anticipates resubmitting the BLA and launching in 2026. Additionally, a second fill/finish facility is being accelerated to ensure supply chain redundancy.
SRK-439: SRK-439, a subcutaneously administered myostatin inhibitor, is advancing into a Phase I study in healthy volunteers by the end of 2025. It is designed to increase muscle mass and has shown potential in preclinical studies.
SMA Market Opportunity: The global SMA treatment market is valued at approximately $5 billion annually. Scholar Rock estimates that 35,000 patients globally who have received SMN-targeted therapies could be eligible for apitegromab.
Manufacturing and Supply Chain: Scholar Rock is addressing supply chain issues by accelerating the development of a second fill/finish facility, expected to be operational in early 2026. This facility will provide redundancy and ensure compliance with regulatory standards.
Financial Position: The company ended Q3 2025 with $369.6 million in cash and expects to extend its runway into 2027. It has deferred certain investments and is focusing on prioritized areas such as apitegromab's launch readiness and pipeline development.
Pipeline Expansion: Scholar Rock is advancing apitegromab for a second rare neuromuscular disorder and has initiated a Phase II OPAL trial for infants and toddlers with SMA. It is also progressing SRK-439 into clinical development.
Regulatory Strategy: The company is working closely with the FDA and Novo Nordisk to address compliance issues at the Bloomington facility. It plans to resubmit the BLA for apitegromab and anticipates approval and launch in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The FDA issued a complete response letter (CRL) for apitegromab due to compliance issues at the third-party fill/finish facility in Bloomington, Indiana, owned by Novo Nordisk. This has delayed the approval and U.S. launch of apitegromab until at least 2026.
Supply Chain Disruptions: Scholar Rock is accelerating plans to add a second U.S.-based fill/finish facility to mitigate risks associated with the Bloomington facility. However, this process is lengthy and requires rigorous validation and regulatory approval, with commercial capacity only available by Q1 2026.
Financial Constraints: The company has deferred investments in hiring, launch expenses, and certain R&D activities to manage its cash runway. While the current cash balance is expected to fund operations into 2027, this assumes no additional delays or unforeseen expenses.
Market Access Challenges: The company is working to broaden engagement with SMA treatment centers and regional payers, but the additional time required for approval may impact the momentum of pre-commercial activities and market readiness.
Strategic Execution Risks: The delay in apitegromab's approval and the need to accelerate a second fill/finish facility could strain resources and impact the timely execution of other pipeline projects, including SRK-439 and additional indications for apitegromab.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Apitegromab Approval and Launch Timeline: Scholar Rock anticipates resubmitting the BLA for apitegromab and expects U.S. launch following approval in 2026. The company is also accelerating timelines for a second fill/finish facility, with commercial capacity secured for Q1 2026 and an sBLA submission planned for later in 2026.
European Market Authorization: A decision from the EMA on apitegromab's Marketing Authorization Application is expected by mid-2026.
Phase II OPAL Study: Scholar Rock has initiated dosing in the Phase II OPAL trial for infants and toddlers under 2 years old with SMA, aiming to assess the efficacy and safety of apitegromab over 48 weeks.
Second Neuromuscular Disorder Indication: Clinical development activities for apitegromab in a second neuromuscular disorder are planned to begin by the end of 2025, with further details to be provided in early 2026.
SRK-439 Development: The company plans to initiate a Phase I study for SRK-439, a subcutaneously administered myostatin inhibitor, in healthy volunteers by the end of 2025, with data expected in 2026.
Financial Guidance: Scholar Rock expects its current cash balance of $369.6 million, augmented by $60 million from warrant exercises, to fund operations into 2027. The company is also exploring non-dilutive financing options to further strengthen its balance sheet.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How does the company plan to approach further financing opportunities, and what is their strategy regarding debt, royalty, and equity?
A:The company aims to bridge financing until approval by first extending their loan facility, as it offers the lowest cost of capital. Royalty would be the next option, and equity would be the last and most expensive option, which they aim to avoid. ATMs are used opportunistically for small capital augmentations.
Q:What operational risks are associated with transitioning from one facility to another during the early days of launch, and how are these risks being addressed?
A:The company is focused on minimizing changes between the primary and secondary vialers to ensure a seamless transition. They have accelerated progress to secure commercial capacity at a second vialer and commenced tech transfer quickly. The impact on the marketplace is expected to be seamless.
Q:How does the company provide confidence that the remediation effort at the Catalent facility is on good footing, and what is the expected classification for the resubmission?
A:The company highlights Novo Nordisk's commitment to quality and compliance, changes in staff, and integration of Novo's quality system. Novo has communicated to the FDA that the facility will be reinspection ready by the end of the year. The classification (Class I or Class II) will depend on the FDA's assessment, but the company is optimistic about the progress.
Q:Why is the company planning to submit the BLA for apitegromab in 2026 with Catalent as the primary fill/finish facility and file an sBLA for the additional facility later?
A:The company believes this is the right path given Novo's progress and commitment to being reinspection ready by year-end. The second vialer was always part of the plan, and its acceleration serves as an insurance policy. The EMA review is proceeding as expected, with a decision anticipated by mid-next year.
Q:What is the latest timeline for the Catalent reinspection to meet the 2026 launch expectations, and what is the contingency plan if the inspection does not resolve all issues?
A:The reinspection could occur well into 2026 and still meet the launch timeline. If the inspection does not resolve all issues, the company could pivot to using the second vialer as the primary resubmission strategy. The FDA may expedite pathways to add the second vialer as the primary facility.
Q:Is the plan to wait for the Catalent reinspection and OAI resolution before submitting the BLA, and has Novo hired outside consultants for the remediation process?
A:The company plans to wait for the reinspection and OAI resolution before resubmitting the BLA. Novo has hired outside experts to assist with the remediation plan and progress.
Q:What could the FDA meeting minutes reveal about the resubmission type and timelines, and what is the expected review process?
A:The minutes may confirm the collaborative tone and urgency discussed during the Type A meeting. The review timelines will be determined after the BLA resubmission, but the agency has shown support for acting with urgency.
Q:What are the disclosure plans regarding the Catalent reinspection and its outcome?
A:The company plans to disclose material information, such as the reinspection timeline and outcome, in a timely manner. They aim to maintain open communication and provide updates as significant developments occur.
Q:Could filing the BLA ahead of the reinspection serve as a forcing mechanism for the FDA to expedite the inspection?
A:The company prefers a collaborative approach with the FDA rather than using the BLA filing as a forcing mechanism. They believe the urgency is already highlighted by pending applications at the Catalent facility and their Type A meeting discussions.
Q:What efforts are being made to identify patients ahead of the apitegromab launch, and how might this impact uptake?
A:The company is engaging with SMA treatment teams, patient advocacy events, and families to understand the patient journey better. They are emphasizing the unmet need, dual modality approach, and safety profile of apitegromab, which could lead to faster uptake post-approval.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about whether filing the BLA ahead of the reinspection could expedite the inspection timeline. They emphasized collaboration with the FDA but did not clarify if this approach would be considered or effective.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BLA launch
CRL
Chairman
Compliance President
II OPAL
III SAPPHIRE
Office Compliance
Phase II
Phase III
President Cure
RD activity
SMA representative
Type meeting
agency neurology
balance sheet
cash runway
clarity
commitment SMA
compensation
decision maker
division Office
efficacy
fill finish
finish facility
inhibitor
launch approval
leader decision
maker agency
matter
medicine
meeting person
minute
remediation
timeline
SRRK Transcript
Scholar Rock Holding Corporation (SRRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Scholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call reflects a mixed outlook. Positive revenue growth of 25% and a slight improvement in net loss are offset by increased R&D and G&A expenses. Regulatory hurdles, market conditions, and supply chain risks present uncertainties. The absence of shareholder return discussions and unclear management responses in the Q&A add to the neutral sentiment. The strategic initiatives are promising but hinge on future regulatory approvals and market conditions. Overall, the stock is likely to remain stable in the short term.
Scholar Rock Holding Corporation (SRRK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-12
SRRK Slides
SRRK Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
